查看购物车
  • Traditional Chinese
  • Japanese
封面
市场调查报告书
商品编码
1917312

体外诊断展望（2026）

In Vitro Diagnostics Business Outlook, 2026
出版日期: | 出版商: Kalorama Information | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

体外诊断 (IVD) 产业是现代医学的基础性领域，它使临床医生能够检测疾病、监测健康状况并做出精准的治疗决策。随着医疗保健的不断发展，在糖尿病和心血管疾病等慢性病发病率上升以及持续和新出现的传染病威胁的推动下，IVD 市场正在经历持续的变化和增长。

"体外诊断展望" 是一份月刊，旨在帮助业内人士在这个快速变化的环境中保持最新动态。该刊每年出版 12 期，每期聚焦在 IVD 产业的不同细分领域，提供及时的洞察、独家数据和深入的分析。

主要内容

每期月刊提供：

市场数据与预测

详细的成长率、市场规模和市场占有率将帮助您发现新的机会。

全面市场展望

体外诊断 (IVD) 产业主要检测类别和主要参与者的概况。

併购追踪

关于影响市场的併购、收购、合作和联盟的最新资讯。

产业与区域趋势观察

按地区和细分市场进行的趋势分析，可协助您制定客製化策略。

深度新闻分析

关于关键趋势和事件的报告，包括您在其他任何地方都找不到的独家资讯。

2026 年编辑政策

主题每月更新，以反映不断变化的行业重点。 2026年，订阅用户将获得以下特别内容：

  • 报销趋势
  • 品质控制试剂
  • 心臟标记
  • 性传染感染 (STI) 现场检测
  • 非呼吸道传染病
  • 体外诊断市场趋势分析
  • 呼吸道检测市场预测（至2027年）
  • 以及更多内容

"体外诊断展望" 每月直接向订阅用户提供重点突出、切实可行的信息，帮助决策者预测市场变化、识别增长机会，并自信地驾驭复杂的全球体外诊断行业。

目录

市场分析：报销

  • 体外诊断 (IVD) 报销概览
  • 展望：报销

高阶主管新闻简报

  • 简报
    • Kiffik Biomedical 完成 A 轮融资
    • NeoGenomics 任命 Jack Kenny 为董事会成员
    • Cardio Diagnostics 在印度推出高精准度先天性心臟病 (CHD) 检测
    • Cyclomics 完成 250 万欧元融资
    • Truvian 任命新的首席医疗官兼首席策略官
    • Alamar Biosciences 获得 5,000 万美元新融资
    • Alamar Biosciences 迎来新的首席科学官
    • Hummingbird Diagnostics 任命新的首席执行官
    • Precede Biosciences 融资 8,350 万美元

财务亮点

  • 安捷伦宣布 2025 财年营收年增 7%

诊断市场併购及合作协议

  • 併购
  • 合作

产业观察

  • 产业观察：新冠疫情/流感最新动态

区域观察

  • 澳大利亚

博德公司公告

  • 公告
    • Mira Precision Health 在美国推出 ToxNav
    • Beckton Dickinson 获得 FDA 批准和 CE 认证
    • QuidelOrtho 的 VITROS 免疫诊断产品获得 FDA 批准
    • FDA 提议对伴随诊断检测进行重新分类
    • 国会就 PAMA 法案展开辩论
    • MeMed 加速人工智慧驱动的急诊诊断
    • Truvian Health 的九项新增分析获得批准
简介目录
Product Code: 26-014KA

The in vitro diagnostics (IVD) industry is a cornerstone of modern healthcare, empowering clinicians to detect disease, monitor health conditions, and guide treatment decisions with precision. As healthcare continues to evolve-driven by rising rates of chronic conditions such as diabetes and cardiovascular disease, along with ongoing and emerging infectious threats-the IVD market is undergoing constant change and growth.

In Vitro Diagnostics Business Outlook is a monthly intelligence publication designed to help industry professionals stay current in this fast-moving environment. Delivered in 12 issues annually, each issue focuses on a different segment of the IVD industry, providing timely insights, exclusive data, and in-depth analysis.

Featured Content

Each monthly issue provides:

Market Data and Forecasts

Detailed growth rates, market size, and market share to help identify emerging opportunities.

Comprehensive Market View

Coverage of key test categories and profiles of active companies across the IVD landscape.

M&A Activity Tracking

Updates on mergers, acquisitions, partnerships, and collaborations shaping the market.

Industry & Region Watch

Analysis of regional and segment-specific trends to support tailored strategic planning.

In-Depth News Analysis

Reporting on significant developments and events, including exclusive information not readily available elsewhere.

2026 Editorial Focus

Topics vary month to month, reflecting evolving industry priorities. In 2026, subscribers can expect issues dedicated to:

  • Reimbursement trends
  • Quality control reagents
  • Cardiac markers
  • STI point-of-care testing
  • Non-respiratory infectious diseases
  • An overall IVD market trend analysis
  • A forward-looking forecast of the respiratory testing market through 2027
  • And more!

By delivering focused, actionable intelligence directly to subscribers' each month, In Vitro Diagnostics Business Outlook helps decision-makers anticipate market shifts, identify growth opportunities, and navigate the complexities of the global IVD industry with confidence.

Table of Contents

Market Analysis: Reimbursement

  • Overview of IVD Reimbursement
  • Outlook: Reimbursement
    • Figure: CMS Average Reimbursement Trend: 40+ High-Frequency Clinical Laboratory Test Codes
    • Table: CMS Reimbursement Limit by Clinical Laboratory Test Code, 2010, 2015, 2020, and 2025
    • Table: Select Companies/Products Expected 2026 Reimbursement Impact
    • Table: Summary of Key Reimbursement Drivers

Executive News Briefing

  • Briefings
    • Kiffik Biomedical Closes Series A Financing
    • NeoGenomics Appoints Jack Kenny to Board of Directors
    • Cardio Diagnostics Launches Precision CHD Test in India
    • Cyclomics Closes Euro-2.5 Million Investment Round
    • Truvian Appoints New Chief Medical and Strategy Officer
    • Alamar Biosciences Closes $50 Million in New Capital
    • Alamar Biosciences Welcomes New CSO
    • Hummingbird Diagnostics Appoints New CEO
    • Precede Biosciences Nabs $83.5 Million in Total Financing

Financial Highlights

  • Agilent Full Year Fiscal 2025 Sales up 7% in Business YOY
    • Figure: Agilent Sales by Business, FY 2024 and 2025 ($)
    • Figure: Agilent Sales by Business, FY 2025 Quarterly Performance ($)
    • Table: Agilent Revenue Mix, by Type, FY 2025 (%)
    • Figure: Agilent FY 2025 Regional Sales Breakdown Distribution (%)

Diagnostic Market Mergers, Acquisitions, and Partnership Deals

  • Mergers and Acquisitions
    • Table: Recent Diagnostic Market Mergers, Acquisitions, and Partnership Deals
  • Partnerships and Collaborations

Industry Watch

  • Industry Watch COVID-19/Flu Update

Region Watch

  • Australia
    • Figure: Australia Exports, Distribution by Industry Segment, 2023 ($ billion)
    • Figure: Australia IVD Market Sales Trend, 2020-2025 ($ million)

Broad-based Company Announcements

  • Announcements
    • Mira Precision Health Launches ToxNav in U.S.
    • Beckton Dickinson Receives FDA Clearance and CE Marking
    • QuidelOrtho Captures FDA Clearance or VITROS Immunodiagnostic
    • FDA Proposes Reclassification of Companion Diagnostic Assays
    • Congress Discusses PAMA
    • MeMed Accelerates AI-enabled Acute-Care Diagnostics
    • Truvian Health Snags Clearance for Nine Additional Analytes